BeStock  
Stocks › Biotechnology › PTCT

PTC Therapeutics PTCT

US equityMarket cap rank #2094Biotechnology
$56.42 −$1.91 (-3.27%)
Market closed · Nov 20, 8:10 pm ET · Last extended-hours $56.99 +1.01%
Open$58.78
Prev close$58.33
Day range$56.18 – $58.96
Volume952.6K
Market cap$4.71B
P/E (TTM)–
Dividend yield–

Earnings

Average move on report day±8.4%last 16 reports
Closed higher9 of 1656% of the time
Best reaction+14.3%
Worst reaction-22.7%

Stock move on the day after each report

+13.3%2023/Q4+12.1%2024/Q1-3.6%2024/Q2+3.1%2024/Q3+9.3%2024/Q4+12.6%2025/Q1-9.9%2025/Q2+6.0%2025/Q3+1.1%2025/Q4+14.3%2026/Q1-9.9%2026/Q2-7.0%2026/Q3
QuarterReport dateTimingImplied moveActual moveVersus implied
2026/Q329 Oct 2026After Market±14.1%-6.97%Within range
2026/Q230 Jul 2026After Market±10.6%-9.94%Within range
2026/Q17 May 2026After Market±9.3%+14.27%Bigger than priced
2025/Q419 Feb 2026After Market±8.6%+1.09%Within range
2025/Q34 Nov 2025After Market±11.3%+5.98%Within range
2025/Q27 Aug 2025After Market±11.3%-9.89%Within range
2025/Q16 May 2025After Market±12.4%+12.63%Bigger than priced
2024/Q427 Feb 2025After Market±20.2%+9.27%Within range
2024/Q37 Nov 2024After Market±9.4%+3.07%Within range
2024/Q28 Aug 2024After Market±13.8%-3.57%Within range
2024/Q125 Apr 2024After Market±20.3%+12.08%Within range
2023/Q429 Feb 2024After Market±18.2%+13.34%Within range
2023/Q326 Oct 2023After Market±12.8%-22.71%Bigger than priced
2023/Q23 Aug 2023After Market±11.9%-3.99%Within range
2023/Q127 Apr 2023After Market±12.8%+4.75%Within range
2022/Q421 Feb 2023After Market±15.7%-1.10%Within range

"Implied move" is the size of move the options market was pricing ahead of the report. Move is the stock’s change on the first session after the release.

Where the revenue comes from

Quarter 2026/Q3

By business line

  • Sephience$181.89M 50.8%
  • Royalty revenue$81.68M 22.8%
  • Translarna$48.51M 13.6%
  • Emflaza$25.09M 7.0%
  • Upstaza/Kebilidi$14.55M 4.1%
  • All other products$5.85M 1.6%
  • Collaboration and license revenue$229,000.00 0.1%

Latest reported quarter: Q3, ended Sep 2026

Revenue$357.81M+69.6% YoY
Operating profit$25.11M+620.0% YoY
Net profit-$51.69M-425.2% YoY
Diluted EPS-$0.62-410.0% YoY
Free cash flow-$31.33M+90.3% YoY
Operating cash flow-$25.31M

Revenue, last 8 quarters

$213.2MDec '24$1.2BMar '25$178.9MJun '25$211.0MSep '25$164.7MDec '25$272.6MMar '26$360.5MJun '26$357.8MSep '26

Net profit, last 8 quarters

$-65.9MDec '24$866.6MMar '25$-64.8MJun '25$15.9MSep '25$-135.0MDec '25$-2.8MMar '26$83.5MJun '26$-51.7MSep '26

Profitability & balance sheet

Gross margin93.2%
Operating margin12.0%
Net margin-9.2%
Return on assets-3.6%
Current ratio3.27
Liabilities / assets106.0%
Cash & investments$2.13B
Total debt$621.82M
Net cash (debt)$1.51B

Discussion

No comments yet — be the first to weigh in on PTCT.

Sign in to join the discussion.

Scroll to Top